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Gastric adenocarcinoma has a poor prognosis, accounting for 
10 000 deaths per year in the UK. Although its incidence is declining,
it remains the second most common tumour world-wide and the
fourth commonest cancer in Europe. At presentation around 30% of
patients have metastatic disease and a further 30% have locally
advanced disease penetrating the serosal surface of the stomach or
directly invading adjacent organs. With locally advanced disease,
curative surgery is only possible in a minority of patients and recur-
rent disease affects 80% of patients within 5 years of potentially cura-
tive surgery. Therefore the prognosis remains poor with an overall
survival of around 20% at 5 years (Allum et al, 1989).
Combination chemotherapy results in a significant survival
advantage in patients with advanced gastric cancer compared with
best supportive care in randomized clinical trials. High response
rates may be obtained with the use of protracted venous infusional
5-fluorouracil (5-FU), cisplatin and epirubicin – the ECF regimen
(Findlay et al, 1994). In an initial study with this regimen, an
overall response rate of 71% and a complete response rate of 12%
were observed. These encouraging results have been confirmed in
two subsequent studies, with overall response rates of around 60%
and with complete responses occurring in around 10% of patients
(Highley et al, 1994; Zaniboni et al, 1995). In a multi-centre
randomized study, ECF resulted in significantly better response
rate (45%) and median survival (8.9 months), with significantly
less toxicity compared to the FAMtx regimen (Webb et al, 1997).
Consequently the ECF regimen is considered the treatment of
choice for advanced adenocarcinoma of the oesophagus and
stomach by many clinicians in the UK.
This regimen, however, requires protracted venous infusion of
5-FU through a Hickman catheter, which is associated with signif-
icant morbidity. The most common problems encountered are
thrombosis and sepsis requiring line removal in up to 15% of
patients (Webb et al, 1997). Consequently, replacing the contin-
uous infusion of 5-FU by a drug with a related mechanism of
action would overcome the need for inserting a Hickman catheter
and its associated morbidity. As inhibition of thymidylate synthase
(TS) is an important mechanism of action of infusional 5-FU, one
such strategy is to combine epirubicin and cisplatin with a specific
TS inhibitor. TS catalyses the reductive methylation of deoxy-
uridylate (dUMP) to thymidylate (TMP), the rate-limiting step in
the synthesis of deoxythmidine triphosphate (TTP). TTP is the
only nucleotide specifically required for DNA synthesis and has
been postulated as an ideal target for anticancer drugs.
Raltitrexed (tomudex) is a quinazolone-based, water-soluble
anti-folate, which is extensively and efficiently poly-glutamated.
The poly-glutamates are 100 times more potent inhibitors of TS
than the parent drug and are retained intra-cellularly allowing a
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Summary The standard treatment for advanced gastro-oesophageal cancer in the UK is epirubicin, cisplatin and continuous infusion
5-fluoruracil by an indwelling central venous catheter (ECF), which has significant morbidity. Raltitrexed (tomudex), a specific inhibitor of
thymidylate synthase with a long plasma terminal half-life (50–100 h) has activity in gastro-intestinal tract malignancy. To reduce the Hickman
line-associated morbidity of ECF; we have conducted a dose-finding study of tomudex combined with epirubicin and cisplatin. Twenty-four
patients (22 males, two female), median age 63 years (range 21–75), ECOG performance status ≤ 2 with histologically proven, unresectable
or metastatic gastric (14 patients), gastro-oesophageal junction (nine patients) or oesophageal (one patient) adenocarcinoma received
treatment with 3-weekly cisplatin 60 mg m–2, epirubicin 50 mg m–2 and tomudex at doses of 2 mg m–2, 2.5 mg m–2 or 3 mg m–2 in successive
cohorts. Six patients were treated per dose level with no intra-patient dose escalation. Dose escalation occurred after six patients had
completed at least one cycle of chemotherapy at the previous dose level. After defining the maximum tolerated dose a further six patients
were treated at the preceding dose level to assess toxicity at the proposed phase II dose. A total of 102 cycles (50% completed 6 cycles) were
administered. The dose-limiting toxicities are neutropenia and diarrhoea occurring in 2/6 patients at the 3 mg m–2 dose level. Of those patients
evaluable for response, there were eight partial and one complete response (overall response rate 38%). The median survival was 9.9
months. ECT is an active regimen in oesophagogastric adenocarcinoma. The recommended dose of tomudex for further study in combination
with epirubicin and cisplatin is 2.5 mg m–2. © 2000 Cancer Research Campaign
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doi: 10.1054/ bjoc.2000.1165, available online at http://www.idealibrary.com on convenient 3-weekly dosing schedule. The maximum-tolerated
dose of tomudex is 3.5 mg m–2, resulting in severe malaise, nausea,
asthenia and anti-proliferative toxicity including bone marrow and
gastrointestinal toxicity (Clarke et al, 1996). Consequently the
recommended dose for phase II studies was 3 mg m–2. In these
studies, raltitrexed has demonstrated single-agent activity in
colorectal (Jackman et al, 1995), breast (Smith et al, 1996),
pancreatic (Pazdur et al, 1996) and ovarian carcinoma (Gore et al,
1995). In colorectal cancer, randomized trials have shown similar
activity to 5-FU (Cunningham, 1998).
We have therefore conducted a dose-finding study in previously
untreated patients with adenocarcinoma of the oesophagus and
stomach to define the optimal dose of tomudex used in combina-
tion with epirubicin and cisplatin. This will form the basis of
further studies to determine the activity of this regimen with the
aim of avoiding the morbidity of Hickman catheter insertion for
the administration of infusional 5-FU.
PATIENTS AND METHODS
Eligibility criteria
The Local Research Ethics Committee in each of the participating
centres approved this study. All patients entered into this study had
histologically confirmed adenocarcinoma of the stomach, oesoph-
agus or gastro-oesophageal junction Inoperability was determined
on the basis of clinical evaluation, radiological imaging, and
laparoscopy or laparotomy with failed resection. Eligibility
criteria included: estimated life expectancy ³12 weeks; at least one
site of bi-dimensionally measurable disease or evaluable disease;
adequate renal function (calculated creatinine clearance ³60 ml
min–1 by the Cockcroft and Gault formula); adequate hepatic func-
tion (serum bilirubin ≤1.5 times the upper limit of the reference
range, transaminases <5 times the upper limit of the reference
range) and adequate haematological function (haemoglobin ³10 g
dl–1; neutrophil count ³1.5  ´ 109 l–1; platelets ³100  ´ 109 l–1
Patients who had received previous chemotherapy for advanced
disease were excluded. Patients who had received neo-adjuvant or
adjuvant chemotherapy with the ECF regimen were eligible if
more than 1 year had elapsed from the completion of this treat-
ment. Patient performance status was assessed using the ECOG
criteria and those patients with performance status ≤2 were consid-
ered eligible for this study. All patients gave written informed
consent prior to starting treatment.
Chemotherapy
Cisplatin (60 mg m–2) and epirubicin (50 mg m–2) were adminis-
tered on day 1 and then every 21 days for up to a maximum of six
cycles of treatment. Cisplatin was administered as a short intra-
venous infusion with standard pre- and post-hydration protocols,
magnesium and potassium supplementation and anti-emetics
(dexamethasone and granisetron). Raltitrexed was administered as
a short intravenous infusion over 15 min prior to the cisplatin on
day 1 of a 3-weekly cycle. A maximum of six patients were treated
at each of three pre-determined dose levels (2, 2.5 and 3 mg m–2)
and no intra-patient dose escalation was permitted. Dose escala-
tion was performed after all six patients in the previous dose level
had completed at least one cycle of chemotherapy.
Evaluation of toxicity
Chemotherapy toxicity was graded using the NCIC-CTC
expanded common toxicity criteria. Toxicity, performance status
and biochemical profile were assessed prior to each chemotherapy
cycle, and full blood count was performed weekly during all treat-
ment cycles. Dose escalation and determination of dose-limiting
toxicity (DLT) and maximum-tolerated dose (MTD) was on the
basis of toxicity from the first cycle of chemotherapy only.
DLT was defined as grade IV or complicated grade III haemato-
logical toxicity (neutropenia with fever, thrombocytopenia with
bleeding or bruising); grade III/IV non-haematological toxicity
other than alopecia, nausea or vomiting; or stomatitis ³ grade II.
MTD was determined when at least two out of the six patients
treated at that dose level experienced any DLT. Once the MTD was
defined a further six patients were treated at one dose level below
the MTD to gain further experience of the toxicity with this
regimen. Cumulative toxicity was also recorded for all subsequent
chemotherapy cycles at all dose levels.
Dose modifications and delays
Dose modifications were performed on the basis of toxicity.
Administration of all three agents was delayed until adequate
haematological recovery (absolute neutrophil count ³1.5 ´ 109 l–1,
platelets ³100 ´ 109 l–1) up to a maximum of 3 weeks. Dose modi-
fication of epirubicin was based on haematological parameters at
the time that each chemotherapy cycle was due. In the event of
clinically significant thrombocytopenia or an episode of
neutropaenic sepsis, the dose of epirubicin was reduced by 25%
for all subsequent cycles of chemotherapy even if haematological
recovery had occurred at the time of treatment. If patients had
uncomplicated grade IV neutropenia the epirubicin dose was
maintained in subsequent cycles. Raltitrexed dose was not modi-
fied in the face of uncomplicated grade IV myelosuppression if
this had recovered prior to day 21.
For non-haematological toxicity (other than alopecia, nausea
and vomiting), raltitrexed was discontinued for grade IV toxicity
and given at 75% of the starting dose for grade III toxicity respec-
tively. Raltitrexed was given at full dose if the calculated creati-
nine clearance (CCC) was ³ 60 ml min–1, was reduced to 50% of
the starting dose and given at 28-day intervals for CCC 25–
59 ml min–1 and was discontinued for CCC <25 ml min–1.
Cisplatin dose modifications for impaired renal function were
made according to previously published guidelines (Findlay et al,
1994). Cisplatin was administered at full dose if the CCC was 
³ 60 ml min–1, and discontinued if CCC was < 40 ml min–1. For
CCC 40–59 ml min–1 the total dose of cisplatin in milligrams
administered was equivalent to the CCC (e.g. if CCC was 50 ml
min–1 the cisplatin dose was 50 mg). Following a dose reduction
all subsequent doses were administered at the modified dose
unless there was recovery of renal function to normal levels.
Evaluation of response and overall survival
Pretreatment evaluations included a full medical history and
examination, full blood count and biochemical profile including
urea, electrolytes, calculated creatinine clearance and liver func-
tion tests. Computerized tomography (CT) scan of the abdomen
and any other sites of disease as appropriate was performed prior
to starting treatment and repeated after three and six cycles of
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after three and six cycles as response assessment in those with
endoscopically evaluable disease. Evaluation of response was
based on the standard WHO criteria. Subsequently CT scans and
endoscopy were not performed routinely but at the investigator’s
discretion. The time to disease progression was recorded where
known and overall survival curves were calculated using the
Kaplan and Meier method.
RESULTS
Twenty-four eligible patients received a total of 102 cycles of
treatment between 1997 and 1998 at the Beatson Oncology Centre,
Glasgow or at Glasgow Royal Infirmary. The patient characteris-
tics at baseline are summarized in Table 1. Thirteen patients had
previously been treated with surgery alone, and three with both
surgery and radiotherapy. No patients had received previous neo-
adjuvant or adjuvant chemotherapy. The median number of treat-
ment cycles administered per patient was 5.5 (range 1–6) and 50%
of the patients in this study completed six cycles of treatment.
Toxicity (first cycle)
Haematological toxicity
Haematological toxicity following the first cycle of treatment is
summarized in Tables 2 and 3. One patient, at the first dose level 
(2 mg m–2 raltitrexed), had severe haematological toxicity with
grade IV leukopenia, neutropenic sepsis, thrombocytopenia and
renal failure secondary to hypotension as a result of gastroin-
testinal haemorrhage and sepsis. Gastrointestinal haemorrhage had
been a problem prior to commencing chemotherapy in this patient
and, after one cycle of chemotherapy, death occurred from recur-
rent gastrointestinal haemorrhage with thrombocytopenia and
rapidly progressive disease.
In the second cohort (dose level 2.5 mg m–2 raltitrexed), one
patient had uncomplicated grade IV neutropenia after one cycle of
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Table 1 Patient characteristics on study entry
Characteristic Number
Total number of patients 24
M/F 22/2
Median age (years) 63
Range 21–75
Primary tumour
Oesophagus 1 (4%)
Gastro-oesophageal junction 9 (38%)
Gastric 14 (58%)
Histology
Intestinal 5 (21%)
Diffuse 6 (25%)
Unknown 13 (54%)
Stage II 1 (4%)
Stage IIIA 2 (8%)
Stage IIIB 4 (17%)
Stage IV 17 (71%)
Previous treatment
None 8 (33%)
Surgery alone 13 (54%)
Surgery and XRT 3 (13%)
ECOG performance status
0 10 (42%)
1 9 (38%)
2 5 (21%)
Table 2 Haematological toxicity – first cycle only (nadir counts)
Dose of Tomudex Median nadir Median nadir Median nadir
neutrophil count platelet count WCC (range)
(range) (range)
2 mg m–2 (n = 6) 0.69 (0.50–1.80) 206.5 (4–271) 2.24 (0.98–3.50)
2.5 mg m–2 (n = 12) 1.40 (0.37–4.10) 222 (160–441) 3.22 (1.31–6.70)
3 mg m–2 (n = 6) 1.46 (0.10–4.40) 201 (89–411) 2.97 (0.60–6.20)
Median time to nadir = 14 days (range 7–21 days, interquartile range 12–15 days).
Table 3 Haematological toxicity – first cycle only (NCI-CTC grading)
Tomudex Tomudex dose Tomudex
Grade 2.0 mg m–2 (n = 6) 2.5 mg m–2 (n = 12) 3.0 mg m–2 (n = 6)
nn n
22 3 0
Neutropenia 3 4 1 2
40 2 1
23 2 1
Leucopenia 3 1 2 1
41 0 1
20 0 0
Thrombocytopenia 3 0 0 0
41 0 0
21 4 2
Anaemia 3 1 0 0
40 0 0treatment. In the third cohort (dose level 3.0 mg m–2 raltitrexed)
one patient developed complicated grade III and one patient
complicated grade IV neutropenia.
Non-haematological toxicity
Non-haematological toxicity following the first cycle of treatment
is summarized in Table 4. In the first cohort, one patient developed
grade IV diarrhoea and stomatitis after the first treatment (see
below). In the third cohort of patients (raltitrexed 3.0 mg m–2) two
patients experienced grade III or IV diarrhoea after one cycle of
treatment. Biochemical toxicity was mild and was not dose-
limiting in any of the patient cohorts (infra vide).
Toxicity (all other cycles)
Haematological toxicity
The maximum haematological toxicity for all cycles of treatment
and nadir blood counts are summarized in Table 5.
One patient at the first dose level had the fifth cycle of treatment
delayed for neutropenia on day 21. In the second cohort one
patient experienced grade IV uncomplicated neutropenia after
three cycles of treatment. There were no delays in treatment in this
group of patients for toxicity.
Two patients in the third cohort had neutropenic sepsis after
three cycles of treatment. In the fourth cohort (2.5 mg m–2) two
further patients experienced uncomplicated grade IV neutropenia
during their treatment.
Non-haematological toxicity
Worst non-haematological toxicity for all administered cycles is
shown in Table 6. Alopecia, as expected was common. Nausea and
vomiting was well controlled with serotonin antagonists, except
for three patients who had grade III nausea and vomiting. Dose-
limiting non-haematological toxicity occurring after the first cycle
of treatment occurred in two patients treated with 3 mg m–2 of
raltitrexed (diarrhoea and stomatitis in one patient, diarrhoea alone
in one patient). At the expanded dose level of 2.5 mg m–2, one
patient experienced grade IV diarrhoea after three cycles of
treatment.
Biochemistry
Hepatic function One patient in the first cohort developed grade
I reversible transaminitis, 8 days after the first and second cycles
of chemotherapy. This did not recur with subsequent treatments.
One patient in the second cohort developed grade II transaminitis
following one cycle of treatment. This occurred 8 days after treat-
ment and returned to normal on day 13 and was felt to be drug-
related. In the third cohort, one patient had grade I and one patient
grade II transaminitis, which was probably drug-related and
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Table 4 Non-haematological toxicity – first cycle only (NCI-CTC grading)
Tomudex Tomudex dose Tomudex
Grade 2.0 mg m–2 (n = 6) 2.5 mg m–2 (n = 12) 3.0 mg m–2 (n = 6
nnn
21 1 2
Nausea 3 0 1 0
20 3 0
Vomiting 3 0 0 0
20 0 0
Diarrhoea 3 0 0 1
41 0 1
20 0 1
Stomatitis 3 0 0 0
41 0 0
20 0 1
Anorexia 3 0 0 0
Table 5 Cumulative haematological toxicity – all cycles (NCI-CTC grading)
Dose level 1 Dose level 2 Dose level 3
Tomudex Tomudex 2.5 mg m–2 Tomudex
2.0 mg m–2 (n = 6) (n = 12) 3 mg m–2 (n = 6)
Grade nnn
20 1 2
Neutropenia 3 5 4 1
41 4 3
24 5 2
Leucopenia 3 1 3 0
41 0 3
20 0 0
Thrombocytopenia 3 0 0 0
41 0 0
21 7 5
Anaemia 3 1 0 0
41 0 0resolved spontaneously. A further patient in the third cohort
developed grade I transaminitis attributed to disease progression.
Renal function There was no evidence of renal toxicity due to
chemotherapy in any cohort. In the first cohort, one patient devel-
oped renal failure as a result of sepsis. At the second dose level,
one patient developed a transient rise in serum creatinine 11 days
following the first cycle of treatment, which returned to normal
after 5 days. One patient at the first dose level (raltitrexed 
2 mg m–2) had a dose reduction in tomudex and cisplatin due to a
fall in calculated creatinine clearance, which subsequently
returned to normal. One patient treated with a dose of 2.5 mg m–2
of tomudex had a dose reduction of both cisplatin and tomudex 
for renal impairment on the third cycle, following which
chemotherapy was discontinued due to disease progression.
DLT and MTD
The DLTs were neutropaenia, diarrhoea and stomatitis occurring in
two patients at the third dose level (3 mg m–2 raltitrexed) after one
cycle of treatment. The MTD of raltitrexed in this combination
was therefore defined as 3 mg/m2. Grade IV neutropenia occurred
in one patient after one cycle and a further two patients after three
cycles of chemotherapy. This was complicated by sepsis in two of
these patients and as a result two subsequent patients at this dose
level received a reduced raltitrexed dose of 2.5 mg m–2 after
completing the first cycle of treatment.
Two patients died during this study. The first patient was a 71-
year-old man with a gastric cancer, who was admitted to hospital 6
days following treatment at the first tomudex dose level with NCI-
CTC grade 3 neutropenia, grade 4 neutropenic sepsis and gastroin-
testinal haemorrhage. Renal failure occurred as a result of the
gastrointestinal haemorrhage and neutropenic sepsis and, despite
treatment with intravenous fluid resuscitation, intravenous antibi-
otic therapy and transfusions of platelets and red cell concentrates,
he died 4 days following hospital admission. Gastrointestinal
bleeding, which had been present prior to treatment, was
considered to have contributed significantly to his death. This was
exacerbated by myelosuppression, thrombocytopenia, and
neutropenic sepsis, and therefore toxicity from chemotherapy also
contributed significantly to this patient’s death, and was the
primary cause of death.
The second patient was treated with 3 mg m–2 of tomudex. Eight
days following the first cycle of treatment she was admitted with
NCI-CTC grade 4 neutropenia with grade 4 diarrhoea, which
required intravenous fluid resuscitation. Twelve days following
treatment she developed grade 4 neutropenic sepsis. Blood
cultures were positive for Streptococcus pneumoniae and she was
treated with appropriate intravenous antibiotics. The fever
resolved after 48 h. Her neutrophil count had recovered to normal
within 6 days of admission to hospital. She then developed
progressive abdominal distension and clinical signs consistent
with a large bowel obstruction, which was confirmed on barium
studies. This was considered to be due to disease progression. Her
condition deteriorated and she developed a marked metabolic
acidosis with normal renal function. Lactic acidosis may have
been present, however serum lactate was not checked. She died 29
days following the administration of chemotherapy. The exact
cause of death was not known and post-mortem examination was
refused. Death was not considered to be due directly to toxicity of
chemotherapy.
Two further patients treated with 3 mg m–2 of tomudex devel-
oped grade 4 diarrhoea along with grade 3 or 4 neutropenia. One of
these patients developed this after one cycle of treatment and the
second after three cycles. Both patients recovered fully after 10
and 8 days respectively following intravenous fluid resuscitation
and anti-diarrhoeal therapy with loperamide.
Response and survival
Of the 24 patients enrolled in the study, 20 patients completed at
least three cycles of therapy and were eligible for response assess-
ment. One further patient had clinically progressive disease after
one cycle of treatment and has been included in the assessment of
response. One patient had a complete response and eight patients
had a partial response to treatment. Six patients had stable disease,
one of these patients, however, had a good endoscopic response to
treatment. Five patients had radiologically progressive disease
after three cycles of treatment. The overall response rate was 38%
Epirubicin, cisplatin and tomudex in oesophagogastric cancer 1929
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Table 6 Cumulative non-haematological toxicity – all cycles (NCI-CTC grading).
Dose level 1 Dose level 2 Dose level 3
Tomudex Tomudex Tomudex
2.0 mg m–2 2.5 mg m–2 3.0 mg m–2
(n = 6) (n = 12) (n = 6)
Grade nn n
Alopecia 3 6 8 4
21 24
Nausea 3 1 1 0
22 21
Vomiting 3 0 1 0
21 10
Diarrhoea 3 0 0 1
41 13
20 01
Stomatitis 3 0 0 0
41 00
Neutropaenic sepsis 1 0 2
20 12
Anorexia 3 0 0 1(95% confidence interval (CI) 21–55%) based on all patients
entered into the study.
Three patients were ineligible for response assessment; one
patient died from sepsis and gastro-intestinal bleeding after the
first cycle of treatment, one patient had treatment discontinued due
to grade IV diarrhoea after the first cycle and a further patient 
had treatment discontinued after one cycle due to early clinical
deterioration.
At the time of writing, 15 patients have died. The median
follow-up for the nine patients still alive is 8.1 months (range
5.3–15.2 months). The median survival after study entry was 9.9
months (range 0.7–15.2 months). The estimated survival at 6
months is 58% (95% CI 38–77%) (Figure 1).
DISCUSSION
The recommended dose of raltitrexed in combination with epiru-
bicin and cisplatin for further evaluation is 2.5 mg m–2. At this
dose level, six patients (50%) completed six cycles and five
patients (42%) completed at least three cycles of treatment.
Toxicity was mild, although one patient developed grade IV diar-
rhoea after three cycles of treatment, and there was no evidence of
cumulative haematological toxicity. Three patients experienced a
mild elevation in hepatic transaminases. This is a recognized toxi-
city for tomudex, which is asymptomatic, and is only rarely dose-
limiting (Clarke et al, 1996). The DLT for this combination is
neutropaenia, diarrhoea and stomatitis.
Recent pharmacokinetic studies suggest that up to 60% of
raltitrexed clearance is accounted for by renal excretion (Clarke
et al, 1996; Beale et al, 1998). It is therefore of interest that renal
toxicity with the combination of raltitrexed and cisplatin was
minimal. The use of the Cockroft and Gault formula to calculate of
creatinine clearance has recently been criticized, especially where
this is the basis for calculation of carboplatin dosage according to
AUC, as it tends to underestimate creatinine clearance compared
to other methods such as inulin clearance and 24-h urinary creati-
nine clearance (Fliser et al, 1999). Consequently it was considered
that this method of calculating creatinine clearance was adequate
to assess renal function prior to each cycle of treatment, as the
purpose of this assessment was to determine a level of renal func-
tion below which dose modification should be performed to
prevent toxicity.
Clinical data regarding the use of raltitrexed in gastric cancer
are scarce. A single study has demonstrated no activity (Meropol
et al, 1996). However more than 50% of patients in that study had
received previous 5-FU-based chemotherapy. It is known that the
mechanisms of resistance to raltitrexed in vitro include reduced
poly-glutamation of raltitrexed and increased expression of TS
(Jackman et al, 1995). Increased TS expression may also be
induced by 5-FU and correlates with reduced response rate to
5-FU-based treatment. It is also associated with a poor prognosis
in patients with gastric cancer (Johnston et al, 1995; Lenz et al,
1996; Boku et al, 1998; Metzger et al, 1998; Yeh et al., 1998). The
level of expression of TS is likely to be a clinically relevant
predictor for response to raltitrexed and may explain the lack of
response seen in the above phase II study, given the number of
patients who had received previous 5-FU-based chemotherapy.
Laboratory studies, in ovarian cancer cell lines, suggest that the
cytotoxic effects of raltitrexed and cisplatin are at least additive
and may be synergistic (Kelland et al, 1995). It is therefore
possible that raltitrexed in combination with cisplatin in the treat-
ment of gastric cancer may result in improved response rates
compared to either agent on its own, in the absence of preclinical
data to suggest antagonism.
The purpose of this study was to define the optimal dose of
raltitrexed in combination with epirubicin and cisplatin for use in
further studies. Nonetheless, this combination is clearly active in
patients with advanced gastro-oesophageal cancer with an overall
response rate of 38% in a limited number of evaluable patients.
Whilst this is lower than the phase II response rates initially
obtained with infusional 5-FU in combination with epirubicin and
cisplatin (Findlay et al, 1994; Zaniboni et al, 1995), it is similar to
that obtained with other platinum-containing regimens (Elliott et
al, 1990; Sparano et al, 1990; Lacave et al, 1991; Cervantes et al,
1993; Bajetta et al, 1994, 1998; Taal et al, 1994; Kondo et al, 1996;
Cheng et al, 1998) or with ECF in randomized studies (Webb et al,
1997). The median survival of 9.9 months compares with 8.9
months obtained with ECF and between 7 and 11 months with
other cisplatin-based therapies (Lacave et al, 1991; Cervantes et al,
1993; Bajetta et al, 1999, 1998; Kondo et al, 1996; Cheng et al,
1998). We therefore conclude that the optimal dose of raltitrexed is
2.5 mg m–2 when used in combination with epirubicin and
cisplatin. A multi-centre phase II study of this regimen is in
progress with the aim of determining the activity of this regimen in
oesophagogastric cancer. If this demonstrates a response rate of
greater than 40% with sufficient confidence, a randomized phase
III comparison with ECF would be appropriate.
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